Department of Cornea and Refractive Surgery, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, India.
Indian J Ophthalmol. 2021 Dec;69(12):3473-3477. doi: 10.4103/ijo.IJO_3822_20.
To evaluate the effect of topical cyclosporine 0.05% and osmoprotective lubricating eye drops on patients with dry eye disease (DED) with inflammation as measured by raised tear matrix metalloproteinases (MMP-9).
This prospective study included 106 eyes of 53 patients diagnosed with DED based on any of the following DED criteria (Ocular Surface Disease Index [OSDI] score >12, tear film breakup time [TBUT] <10 s, Schirmer's I test result <10 mm/5 min, ocular surface staining). Ocular surface inflammation was assessed by assessing MMP-9 positivity from tears of the patients in the study (Inflammadry kit Quidel corporation). Patients were prescribed osmoprotective lubricating eye drops (Osmodrops, Cipla Ltd) four times a day and cyclosporine A 0.05% eye drops (Imudrops, Cipla Ltd) twice a day for 6 months. Efficacy of the formulations was evaluated by OSDI scores, Schirmer's test, TBUT change, reduction in ocular surface staining, and reduction in MMP-9 levels after 6 months of usage. Check P value and add from results.
After 6 months of topical therapy, improvement was observed in OSDI scores (mean pretreatment: 25.7 ± 12.8, and mean posttreatment: 15.2 ± 8.4), P < 0.001. There was also reduction number of patients who were MMP-9 positive. Out of 75 eyes that tested MMP-9 positive, 70.66% showed reduction in MMP-9 levels P < 0.0001). Ocular surface staining also improved.
Topical osmoprotective lubricating eye drops and cyclosporine A 0.05% reduce inflammation in cases of DED, which correlates with improvement in OSDI scores, ocular surface staining, and reduction in inflammation as measured by levels of tear MMP-9.
评估局部环孢素 0.05％和渗透压保护润滑滴眼液对炎症性干眼疾病（DED）患者的疗效，通过提高泪液基质金属蛋白酶（MMP-9）来衡量。
本前瞻性研究纳入了 53 例患者的 106 只眼，这些患者均基于以下任何一项 DED 标准被诊断为 DED（眼表面疾病指数[OSDI]评分> 12、泪膜破裂时间[TBUT] <10 s、Schirmer 氏 I 试验结果< 10 mm/5 min、眼表面染色）。通过评估研究中患者泪液中的 MMP-9 阳性（Quidel 公司的 Inflammadry 试剂盒）来评估眼表面炎症。患者被处方渗透压保护润滑滴眼液（Osmodrops，Cipla Ltd），每日四次，环孢素 A 0.05％滴眼液（Imudrops，Cipla Ltd），每日两次，持续 6 个月。通过 OSDI 评分、Schirmer 测试、TBUT 变化、眼表面染色减少以及使用 6 个月后 MMP-9 水平降低来评估制剂的疗效。检查 P 值并添加结果。
局部治疗 6 个月后，OSDI 评分（平均治疗前：25.7 ± 12.8，平均治疗后：15.2 ± 8.4）有所改善，P < 0.001。也有更多的 MMP-9 阳性患者数量减少。在 75 只检测 MMP-9 阳性的眼中，70.66％的 MMP-9 水平降低，P < 0.0001）。眼表面染色也有所改善。
局部渗透压保护润滑滴眼液和环孢素 A 0.05％可减少 DED 患者的炎症，这与 OSDI 评分、眼表面染色的改善以及通过泪液 MMP-9 水平衡量的炎症减轻相关。
